Setting the stage for next-generation risk assessment with non-animal approaches: the EU-ToxRisk project experience.


Journal

Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615

Informations de publication

Date de publication:
10 2020
Historique:
received: 21 07 2020
accepted: 12 08 2020
pubmed: 5 9 2020
medline: 7 8 2021
entrez: 5 9 2020
Statut: ppublish

Résumé

In 2016, the European Commission launched the EU-ToxRisk research project to develop and promote animal-free approaches in toxicology. The 36 partners of this consortium used in vitro and in silico methods in the context of case studies (CSs). These CSs included both compounds with a highly defined target (e.g. mitochondrial respiratory chain inhibitors) as well as compounds with poorly defined molecular initiation events (e.g. short-chain branched carboxylic acids). The initial project focus was on developing a science-based strategy for read-across (RAx) as an animal-free approach in chemical risk assessment. Moreover, seamless incorporation of new approach method (NAM) data into this process (= NAM-enhanced RAx) was explored. Here, the EU-ToxRisk consortium has collated its scientific and regulatory learnings from this particular project objective. For all CSs, a mechanistic hypothesis (in the form of an adverse outcome pathway) guided the safety evaluation. ADME data were generated from NAMs and used for comprehensive physiological-based kinetic modelling. Quality assurance and data management were optimized in parallel. Scientific and Regulatory Advisory Boards played a vital role in assessing the practical applicability of the new approaches. In a next step, external stakeholders evaluated the usefulness of NAMs in the context of RAx CSs for regulatory acceptance. For instance, the CSs were included in the OECD CS portfolio for the Integrated Approach to Testing and Assessment project. Feedback from regulators and other stakeholders was collected at several stages. Future chemical safety science projects can draw from this experience to implement systems toxicology-guided, animal-free next-generation risk assessment.

Identifiants

pubmed: 32886186
doi: 10.1007/s00204-020-02866-4
pii: 10.1007/s00204-020-02866-4
pmc: PMC7502065
doi:

Types de publication

Letter Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3581-3592

Références

Arch Toxicol. 2018 Mar;92(3):1225-1247
pubmed: 29164306
Nat Commun. 2020 Mar 13;11(1):1393
pubmed: 32170132
ALTEX. 2018;35(2):268-271
pubmed: 29984806
iScience. 2020 Feb 21;23(2):100860
pubmed: 32058971
Arch Toxicol. 2019 Jun;93(6):1609-1637
pubmed: 31250071
Hepatology. 2011 Jun;53(6):2027-41
pubmed: 21433042
Arch Toxicol. 2020 Jan;94(1):1-58
pubmed: 31848664
ALTEX. 2020 Apr 30;:
pubmed: 32369604
ALTEX. 2008;25(2):91-102
pubmed: 18551232
ALTEX. 2019;36(4):682-699
pubmed: 31658359
Toxicol Sci. 2018 Sep 1;165(1):198-212
pubmed: 30007363
Nucleic Acids Res. 2018 Jan 4;46(D1):D1266-D1270
pubmed: 29069414
ALTEX. 2020;37(3):490-492
pubmed: 32686838
Environ Mol Mutagen. 2017 Jun;58(5):264-283
pubmed: 27650663
Int J Mol Sci. 2020 Jun 01;21(11):
pubmed: 32492937
Hepatology. 2013 Feb;57(2):727-39
pubmed: 22987284
Mutat Res. 2017 Jul;819:31-37
pubmed: 28622828
ALTEX. 2018 Dec 20;36(2):289-313
pubmed: 30570669
J Cheminform. 2018 Dec 10;10(1):60
pubmed: 30536051
Arch Toxicol. 2018 Feb;92(2):893-906
pubmed: 28965233
Arch Toxicol. 2019 Feb;93(2):435-451
pubmed: 30456486
Environ Health Perspect. 2014 Aug;122(8):796-805
pubmed: 24727499
Front Genet. 2018 Nov 12;9:508
pubmed: 30483308
Reprod Toxicol. 2020 Apr;93:219-229
pubmed: 32114065
Arch Toxicol. 2018 May;92(5):1797-1814
pubmed: 29502165
Front Genet. 2018 Dec 03;9:558
pubmed: 30559759
Cell Death Differ. 2018 Dec;25(12):2101-2117
pubmed: 30390092
ALTEX. 2018 Mar 8;35(2):163-168
pubmed: 29529324
Arch Toxicol. 2018 Aug;92(8):2517-2531
pubmed: 30008028
Arch Toxicol. 2019 Feb;93(2):385-399
pubmed: 30426165
Toxicol Sci. 2014 Jul;140(1):144-59
pubmed: 24752500
Arch Toxicol. 2018 Jan;92(1):41-82
pubmed: 29209747
ALTEX. 2019 Nov 02;37(2):187-196
pubmed: 31707421
Methods Mol Biol. 2019;1981:187-202
pubmed: 31016656
Arch Toxicol. 2020 Feb;94(2):439-448
pubmed: 32060585
Cell Stem Cell. 2018 Jul 05;23(1):101-113.e7
pubmed: 30049452
Arch Toxicol. 2019 Dec;93(12):3643-3667
pubmed: 31781791
Arch Toxicol. 2020 Jul;94(7):2435-2461
pubmed: 32632539
ALTEX. 2020 Feb 28;37(3):364-394
pubmed: 32113184
ALTEX. 2008;25(2):103-14
pubmed: 18551234
Pharm Res. 2018 Dec 27;36(2):28
pubmed: 30591975
Environ Health Perspect. 2016 Nov;124(11):1671-1682
pubmed: 27091369
PLoS One. 2018 Sep 17;13(9):e0203869
pubmed: 30222766
Arch Toxicol. 2019 Jun;93(6):1585-1608
pubmed: 31190196
Arch Toxicol. 2020 Jun;94(6):2263-2272
pubmed: 32447523
Food Chem Toxicol. 2018 Feb;112:544-550
pubmed: 28366846
Cells. 2020 May 01;9(5):
pubmed: 32369990
Arch Toxicol. 2020 Jan;94(1):205-217
pubmed: 31919559
Arch Toxicol. 2020 Jan;94(1):151-171
pubmed: 31712839
ALTEX. 2020 Mar 07;37(3):409-428
pubmed: 32150624
Future Sci OA. 2019 Sep 10;5(8):FSO413
pubmed: 31534781
Toxicol In Vitro. 2013 Dec;27(8):2264-72
pubmed: 24041534
ALTEX. 2019 Dec 12;37(1):155-163
pubmed: 31833558
Arch Toxicol. 2016 May;90(5):1021-4
pubmed: 27017488
Toxicol In Vitro. 2019 Aug;58:42-50
pubmed: 30599189
Arch Toxicol. 2019 Oct;93(10):2895-2911
pubmed: 31552476
ALTEX. 2014;31(3):341-56
pubmed: 25061899
Toxicol Sci. 2019 Jun 1;169(2):317-332
pubmed: 30835285
Mol Inform. 2020 May;39(5):e2000005
pubmed: 32108997
Gastroenterology. 1997 Mar;112(3):923-34
pubmed: 9041255
ALTEX. 2018 Feb 23;35(3):306-352
pubmed: 29485663
J Chem Inf Model. 2018 Aug 27;58(8):1501-1517
pubmed: 29949360
Int J Toxicol. 2015 Jul-Aug;34(4):346-8
pubmed: 25804424
Arch Toxicol. 2018 Dec;92(12):3505-3515
pubmed: 30317417
Stem Cell Res Ther. 2019 Nov 4;10(1):317
pubmed: 31685034

Auteurs

M J Moné (MJ)

Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

G Pallocca (G)

CAAT-Europe at the University of Konstanz, Constance, Germany.

S E Escher (SE)

Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.

T Exner (T)

Edelweiss Connect GmbH, Basel, Switzerland.

M Herzler (M)

German Federal Institute for Risk Assessment (BfR), Berlin, Germany.

S Hougaard Bennekou (SH)

Technical University of Denmark, Kongens Lyngby, Denmark.

H Kamp (H)

BASF SE, Ludwigshafen, Germany.

E D Kroese (ED)

TNO Innovation for Life, Utrecht, The Netherlands.

Marcel Leist (M)

CAAT-Europe at the University of Konstanz, Constance, Germany. marcel.leist@uni-konstanz.de.
In Vitro Toxicology and Biomedicine, Department Inaugurated By the Doerenkamp-Zbinden Foundation at the University of Konstanz, University of Konstanz, 78457, Constance, Germany. marcel.leist@uni-konstanz.de.

T Steger-Hartmann (T)

Investigational Toxicology, Bayer AG, Pharmaceuticals, Berlin, Germany.

B van de Water (B)

Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH